Avastin for Malignant Pleural Mesothelioma – Details


( Last Updated : April 11, 2017)
Generic Name:
Bevacizumab
Project Status:
Withdrawn
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Avastin
Project Line:
Reimbursement Review
Project Number:
PC0100-000

Details


Strength:
100 mg and 400 mg vials
Tumour Type:
Lung
Indications:
Malignant Pleural Mesothelioma
Funding Request:
In combination with pemetrexed and cisplatin or carboplatin (for cisplatin ineligible patients), for first-line treatment in patients with unresectable malignant pleural mesothelioma
Review Status:
Withdrawn
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
Clarification:
Hoffmann-La Roche Limited requested a voluntary withdrawal of the pCODR 10100 Bevacizumab (Avastin) MPM Submission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue the review as a PAG Submission.
Funding Request:
In combination with pemetrexed and cisplatin or carboplatin (for cisplatin ineligible patients), for first-line treatment in patients with unresectable malignant pleural mesothelioma

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.